Search
Sunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalFor these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. … Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
Synonyms: Sunitinib, SunitinibumSalts: Sunitinib malateSunitinib Action Pathway
smpdb.ca/view/SMP0126868Drug actionSunitinib also affects RET, CSF-1R, and flt3 RTKs. … The primary metabolite mirrors sunitinib's potency in relevant assays.
Regorafenib
go.drugbank.com/drugs/DB08896ApprovedInvestigationalRegorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 201...
Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin
go.drugbank.com/conditions/DBCOND0146859Drugs: SunitinibUnresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
go.drugbank.com/conditions/DBCOND0146858Drugs: SunitinibGastrointestinal Stromal Tumor (GIST)
go.drugbank.com/conditions/DBCOND0037254Adenocarcinoma, Renal
go.drugbank.com/conditions/DBCOND0126095Regorafenib Action Pathway
smpdb.ca/view/SMP0126907Drug actionIt is also used for patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have been previously treated with imatinib mesylate and sunitinib malate.